Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-blind, Partially Randomized, Parallel Group, Multicenter Study to Assess the Efficacy and Safety of 100 mg and 150 mg Monthly Oral Ibandronate in Women With Postmenopausal Osteoporosis Having Completed the Phase III Oral Ibandronate Trial BM16549

NCT00081653 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00081653
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00081653 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-blind, Partially Randomized, Parallel Group, Multicenter Study to Assess the Efficacy and Safety of 100 mg and 150 mg Monthly Oral Ibandronate in Women With Postmenopausal Osteoporosis Having Completed the Phase III Oral Ibandronate Trial BM16549
Lead sponsor
Hoffmann-La Roche
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2004
Completion date
May 31, 2008
Enrollment
719 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

post-menopausal osteoporosis